Curaleaf Holdings, Inc. (OTCMKTS:CURLF) Given Average Recommendation of “Moderate Buy” by Brokerages

Curaleaf Holdings, Inc. (OTCMKTS:CURLF – Free Report) has been given an average rating of “Moderate Buy” by the eight brokerages that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $10.00.

Several research firms recently commented on CURLF. Wedbush restated an “outperform” rating and set a $8.50 price target on shares of Curaleaf in a report on Friday, April 14th. Benchmark cut shares of Curaleaf from a “buy” rating to a “hold” rating in a research note on Friday, May 19th. Finally, Alliance Global Partners reduced their target price on shares of Curaleaf from $11.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, April 14th.

Curaleaf Stock Performance

Curaleaf stock opened at $3.09 on Friday. The firm’s 50 day simple moving average is $2.81 and its 200-day simple moving average is $3.32. The company has a market cap of $1.93 billion and a P/E ratio of -5.73. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.10 and a quick ratio of 0.62. Curaleaf has a fifty-two week low of $2.19 and a fifty-two week high of $7.90.

Curaleaf (OTCMKTS:CURLF – Free Report) last released its earnings results on Monday, May 1st. The company reported ($0.23) earnings per share for the quarter. The firm had revenue of $352.49 million during the quarter. Curaleaf had a negative return on equity of 20.37% and a negative net margin of 28.88%. As a group, equities research analysts predict that Curaleaf will post -0.15 EPS for the current year.

About Curaleaf

(Free Report

Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through Domestic Operations and International Operations segments. The company engages in the cultivation, production, and sale of cannabis products through retail and wholesale channels. In addition, it offers flowers, pre-rolls, flower pods, and dry-herb vaporizer cartridges; concentrates for vaporizing, such as pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, including distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Before you consider Curaleaf, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Curaleaf wasn’t on the list.

While Curaleaf currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here